Literature DB >> 15149161

Clinicopathologic significance of cyclin A expression in colorectal carcinoma.

T Nozoe1, S Inutsuka, M Honda, T Ezaki, D Korenaga.   

Abstract

The clinical significance of cyclin A expression, which has been known to act in the mitotic phase of the cell cycle, as an indicator of malignant potential in human tumors, has been suggested. The aim of this study was to elucidate the significance of immunohistochemical expression of cyclin A in colorectal carcinomas based on a larger study population. Immunohistochemical staining for cyclin A was performed for 167 colorectal carcinomas and the correlation between cyclin A expression and the clinicopathological characteristics was analyzed. One hundred and two carcinomas (61.1%) had cyclin A expression and the other 65 (38.9%) did not. The mean size of the tumors with cyclin A expression was significantly larger than that of tumors without cyclin A expression (p = 0.012). Survival in patients with cyclin A-expressing carcinomas was significantly worse than that in patients with carcinomas without cyclin A expression (p = 0.004). Cyclin A expression (p = 0.030), as well as lymph node metastasis (p = 0.007) and Dukes' stage of the tumors (p < 0.0001) were found to be factors independently associated with unfavorable prognosis in patients with colorectal carcinoma. Our results demonstrated that immunohistochemical expression of cyclin A is an independent prognostic indicator in patients with colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15149161

Source DB:  PubMed          Journal:  J Exp Clin Cancer Res        ISSN: 0392-9078


  4 in total

1.  Differences in protein expression and gene amplification of cyclins between colon and rectal adenocarcinomas.

Authors:  Rolf Aamodt; Kristin Jonsdottir; Solveig Norheim Andersen; Johan Bondi; Geir Bukholm; Ida R K Bukholm
Journal:  Gastroenterol Res Pract       Date:  2009-12-15       Impact factor: 2.260

2.  Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer.

Authors:  Yuchen Guo; Monica Gabola; Rossano Lattanzio; Conception Paul; Valérie Pinet; Ruizhi Tang; Hulya Turali; Julie Bremond; Ciro Longobardi; Chloé Maurizy; Quentin Da Costa; Pascal Finetti; Florence Boissière-Michot; Benjamin Rivière; Céline Lemmers; Séverine Garnier; François Bertucci; Inti Zlobec; Karim Chebli; Jamal Tazi; Rania Azar; Jean-Marie Blanchard; Peter Sicinski; Emilie Mamessier; Bénédicte Lemmers; Michael Hahne
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

3.  Five-point scoring system based on clinicopathological data: A convenient criterion to determine prognosis of patients with colorectal carcinoma.

Authors:  Tadahiro Nozoe; Mayuko Kohno; Tomohiro Iguchi; Takashi Maeda; Takahiro Ezaki
Journal:  Oncol Lett       Date:  2013-01-08       Impact factor: 2.967

4.  miR‑508‑3p suppresses the development of ovarian carcinoma by targeting CCNA2 and MMP7.

Authors:  Fei Guo; Kai Zhang; Meiyue Li; Lei Cui; Guoyan Liu; Ye Yan; Wenyan Tian; Fei Teng; Yanfang Zhang; Chao Gao; Jinping Gao; Yingmei Wang; Fengxia Xue
Journal:  Int J Oncol       Date:  2020-04-27       Impact factor: 5.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.